Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lineage Cell Therapeutics Inc
(NY:
LCTX
)
0.9047
+0.0208 (+2.35%)
Streaming Delayed Price
Updated: 10:35 AM EDT, Sep 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Lineage Cell Therapeutics Inc
< Previous
1
2
3
4
Next >
OpRegen® Data Update to Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
July 13, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics Joins Russell 3000® and Russell Microcap® Indexes
June 28, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage’s OPC1 Cell Therapy for the Treatment of Spinal Cord Injury to Return to Clinical Testing
June 22, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Announces Exclusive Option Agreement With Amasa Therapeutics for Supply and Use of Clinical-Grade Hystem®
June 17, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics Announces Kevin L. Cook to Join as Chief Financial Officer
June 16, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics to Present at Raymond James 2021 Human Health Innovation Conference on June 22, 2021
June 15, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics Set to Join Russell 3000® Index and Russell Microcap® Index
June 09, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics to Host Webinar With Therapeutic Area Experts to Discuss Retinal Tissue Restoration Observed in Dry AMD Patients Treated With OpRegen®
June 03, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics Reports Additional Cases of Retinal Tissue Restoration in Dry AMD Patients Treated With OpRegen® RPE Cells
June 01, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Reports First Quarter 2021 Financial Results and Highlights Significant Progress With All Three Clinical Programs
May 13, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Announces Appointment of Anula Jayasuriya, M.D., PH.D., M.B.A., to Board of Directors
May 05, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 13, 2021
May 04, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
OpRegen® Clinical Data Continues to Demonstrate Improvements in Patients With Dry AMD With Geographic Atrophy
May 03, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage to Present at the B. Riley Securities’ Neuroscience Conference on April 28, 2021
April 26, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Announces Appointment of Dr. Dipti Amin to Its Board of Directors
April 22, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Announces Worldwide License Agreement With Immunomic Therapeutics for an Allogeneic Cell-Based Cancer Immunotherapy Based on Its VAC Platform
April 20, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
OpRegen® Data Update to Be Featured at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Christopher D. Riemann, MD
April 12, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.